69 results about "Immune complex deposition" patented technology

A reagent combination, a kit, a detection system and a detection method for detecting a small molecule substance. In the condition that a solution to be tested does not contain or contains a small amount of the small molecule substance, an antibody binds to a substrate protein conjugate to form an immune complex, a stem-loop structure is generated by means of a complementary pairing among a plurality of nucleic acid molecules, a first fluorescent group excites a second fluorescent group to emit a second fluorescence on the basis of fluorescence resonance energy transfer, and the content of the small molecule substance is calculated. In the condition that the solution to be tested contains a large amount of the small molecule substance, the immune complex and the stem-loop structure cannot be formed, and the second fluorescent group cannot emit the second fluorescent.

The invention discloses a biochemical immunodetection device and a biochemical immunodetection method for ursodesoxycholic acid reduzate, and belongs to the technical field of ursodesoxycholic acid reduzate detection. The ursodesoxycholic acid reduzate detection device comprises a detection box and a lifter at the bottom of the detection box, a dissolution preparation part and a centrifugal part are arranged in the detection box, and the dissolution preparation part can fully dissolve an ursodesoxycholic acid reduzate-containing medicament; the centrifugal part is used for carrying out precipitation separation on the dissolved medicament; the detector can accurately collect fluorescence signals of the immune complex; according to the ursodesoxycholic acid reduzate detection device, the integrated operation of detection test tube fixing, cover opening and transferring, medicament adding, cover closing and plug sealing and dissolving is achieved, the steps of automatic medicament filling, sealing and the like are achieved, the medicament preparation efficiency is greatly improved, efficient and accurate detection of ursodesoxycholic acid reduzate is further achieved, and the detection efficiency is improved. And complex and tedious manual operation is avoided, and the situation that the sample is easily polluted by manual operation is avoided.

Disclosed herein is a method for treating immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) with the factor B inhibitor iptacopan or a pharmaceutically acceptable salt thereof (e.g., iptacopan hydrochloride).

This invention discloses a quantitative test strip for HBV PreS1 antibody based on the AIE molecule, its preparation method, and its applications, relating to the fields of molecular biology, immunology, and biodetection technology. The test strip includes a sample pad, a labeling pad, a nitrocellulose membrane (NC membrane), an absorbent pad, and a base plate. The NC membrane detection line is coated with HBV PreS1 antigen to capture PreS1 antibodies in the sample. The labeling pad contains an immobilized Anti-Human IgG antibody conjugated to the AIE molecule, which binds to the PreS1 antibodies in the sample to form an immune complex. The test strip of this invention enables rapid detection of PreS1 antibodies and achieves enhanced fluorescence in the detection results. Combined with a fluorescence reader or fluorescence card reader, the detection results can be digitally and quantitatively analyzed. It is simple to operate, rapid in detection, and significantly improves detection sensitivity and enables quantitative analysis.

The invention belongs to the technical field of genetic engineering antibodies, and particularly relates to an antibody for non-competitive detection of aflatoxin B1 and application of the antibody. The antibody comprises a nano antibody of an anti-aflatoxin B1 antigen-antibody immune complex and a monoclonal antibody of the anti-aflatoxin B1; the amino acid sequence of the nano antibody of the anti-aflatoxin B1 antigen-antibody immune complex is as shown in SEQ ID NO. 1; the monoclonal antibody for resisting aflatoxin B1 comprises a heavy chain and a light chain; the amino acid of the heavy chain is as shown in SEQ ID NO.10, and the amino acid of the light chain is as shown in SEQ ID NO.11. The antibody for non-competitive detection of aflatoxin B1 provided by the invention is low in cost, can be prepared on a large scale through a prokaryotic expression system, is simple and convenient to prepare, has strong operability, and can be applied to non-competitive immunological analysis of aflatoxin B1.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The application discloses a kind of lipoprotein detection reagent and lipoprotein detection method, it is related to biochemical detection technical field, the lipoprotein detection reagent includes R1 reagent and R2 reagent, wherein, the R1 reagent includes anti apolipoprotein B antibody, the R2 reagent includes latex microsphere coated with lipoprotein specificity antibody. Wherein, anti apolipoprotein B antibody can preliminarily enrich target lipoprotein and form immune complex to amplify detection signal, and lipoprotein specificity antibody can specifically recognize target protein and form immune complex-lipoprotein specificity antibody-latex microsphere complex, further amplify detection signal, significantly improve the detection sensitivity of reagent.

The invention discloses a CD16 antibody and application thereof, the CD16 antibody comprises an antibody specifically binding to CD16A and an antibody strongly binding to CD16B but weakly binding to CD16A, the antibody specifically binding to CD16A can bind to CD16A but not binding to CD16B, and selectively activates NK cells and macrophages, so that adverse inflammatory reaction caused by cross reaction of CD16B is avoided; the antibody which is strongly combined with CD16B but weakly combined with CD16A has unique CD16B combining capacity, and can be used for enhancing the function of neutrophil and promoting immune complex removal, so that inflammatory response is regulated; the two antibodies can be developed into a plurality of drugs, have a wide application field, and provide a valuable technical platform for subsequent development of novel antibody drugs.

This application discloses antibodies or antigen-binding fragments thereof that specifically bind to estradiol, immune complexes comprising the same, single-chain antibodies that specifically bind to the immune complexes, methods for their preparation, and uses. The antibody or antigen-binding fragment specifically binding to estradiol comprises a first heavy chain variable region and a first light chain variable region; wherein the first heavy chain variable region comprises first heavy chain CDR1, first heavy chain CDR2, and first heavy chain CDR3, and the first light chain variable region comprises first light chain CDR1, first light chain CDR2, and first light chain CDR3, and each of the six CDRs comprises an amino acid fragment with the sequence shown in SEQ ID NO: 1-6. Applying this antibody or antigen-binding fragment specifically binding to estradiol, along with ScFv selected based on it, to the sandwich method for detecting E2 in serum can significantly reduce background signal and improve the signal-to-noise ratio.

This invention relates to the field of biological detection, and more particularly to the preparation method and application of the t-PAI·C detection kit. The invention provides a detection reagent comprising: antibody-coated magnetic microparticles and enzyme-labeled antibodies; the antibodies include: tissue plasminogen activator-plasminogen activator inhibitor-1 complex antibody. In the detection reagent provided by this invention, when the sample contains the tissue plasminogen activator-plasminogen activator inhibitor-1 complex, the antibody coated with the magnetic microparticles and the enzyme-labeled antibody undergo an immune reaction with the complex, forming a sandwich-like immune complex consisting of the antibody coated with the magnetic microparticles, the complex, and the enzyme-labeled antibody; the enzyme on this complex acts on a luminescent substrate and emits light, and the concentration of the complex in the sample is calculated by detecting the luminescence signal.

The invention discloses a high-sensitivity Tau-441 electrochemical immunosensor based on a nano material synergistic amplification effect as well as a preparation method and application of the high-sensitivity Tau-441 electrochemical immunosensor. According to the sensor, a silk-screen printing electrode (SPE) is used as a substrate, a PEDOT: PSS / MWCNTs-COOH nanocomposite modified working electrode is used as a sensing platform, and electron transfer is promoted by using the large specific surface area and excellent conductivity of the PEDOT: PSS / MWCNTs-COOH nanocomposite modified working electrode. Meanwhile, gold-modified magnetic nanoparticles (Fe3O4-coated AuNPs) are prepared as a signal probe, and the magnetic separation and enrichment function of Fe3O4 and the biocompatibility and catalytic activity of the gold nanoparticles are combined. The sandwich immune complex is constructed by adopting a homogeneous reaction mode, so that the mass transfer resistance is effectively reduced, and the detection time is shortened. The sensor has an extremely low detection limit (19.68 fgmL <-1 >) and a wide linear range on an Alzheimer's disease marker Tau-441, is high in specificity and good in stability, and is suitable for early-stage rapid screening of human plasma samples.

The invention discloses a flow type single molecule detection probe and method based on rolling circle amplification and application in the technical field of biomolecule detection. The flow type single molecule detection probe comprises a plurality of groups of magnetic bead detection probes and antibody binding probes which are used in pairs, each magnetic bead detection probe comprises a superparamagnetic microsphere, and the surface of the superparamagnetic microsphere is covalently connected with a plurality of fixed antibody probes; each fixed antibody probe comprises a first antibody and a first fixed DNA chain; each antibody binding probe comprises a second antibody and a second fixed DNA chain; aiming at the same target antigen, the first antibody and the second antibody in the same group can be specifically combined with different epitopes of the target antigen to form a sandwich immune complex. According to the invention, the hairpin structure DNA probe is combined with the adjacent ligation and rolling circle amplification technology to form dual specific screening of immune recognition and DNA ligation, so that the signal-to-noise ratio and sensitivity of detection are remarkably improved, and the design complexity, development cost and cross reaction risk of a multi-target detection system are greatly reduced.

The invention relates to application of hispidulin or pharmaceutically acceptable salts, esters and solvates thereof in preparation of medicines for treating lupus nephritis. The invention develops a new application of the hispidulin, and proves the treatment effect of the hispidulin on lupus nephritis. Meanwhile, the invention verifies that the hispidulin can obviously improve the renal function indexes (including reducing urine protein, blood urea nitrogen and serum creatinine, increasing serum albumin and improving lipid metabolism) of lupus nephritis, can relieve renal pathological injuries (including reducing glomerular mesangial hyperplasia, basilar membrane thickening, renal tubule dilatation and interstitial inflammation infiltration), and can improve the renal function indexes of lupus nephritis. Kidney immune complex deposition can be reduced (including reduction of deposition of kidney IgG and complement C3), meanwhile, it is found for the first time that angiogenin-like protein 4 (Angptl4) is a key action target for treating lupus nephritis by means of the homospidulin, and the homospidulin plays a kidney protection role by down-regulating Angptl4 expression.

The invention discloses a kit for quantitatively detecting an HBsAg-HBsAb immune complex and application of the kit. The kit provided by the invention is a detection kit based on an ELISA sandwich method, a novel double-antibody sandwich ELISA detection platform provided by the invention adopts an HBsAg specific mSA1 antibody as a capture carrier, and efficient solid phase coating is realized through specific binding of the HBsAg specific mSA1 antibody with HBsAg; meanwhile, an anti-human IgG-HRP conjugate is introduced as a detection antibody, and high-sensitivity and high-specificity quantitative detection of the HBsAg-HBsAb immune complex is realized by utilizing special epitopes of different subtypes of human IgG and the catalytic amplification effect of HRP. The detection kit disclosed by the invention provides a reliable tool for quantitatively detecting the HBsAg-HBsAb immune complex for clinical use.

The application belongs to the technical field of nanomaterials and biological analysis, and particularly relates to a ratio type photoelectrochemical analysis method based on multifunctional CeO2 / CdS and interface etching. First, a multifunctional CeO2 / CdS nanocomposite is synthesized by an in-situ growth method, and the nanocomposite has photoelectric properties of CdS and CeO2 peroxidase activity; second, a beacon antibody labeled with nanogold and glucose oxidase is prepared by an electrostatic adsorption method, a target protein, the beacon antibody and an antibody coated on an enzyme-labeled microplate are mixed and incubated to form an immune complex, and after glucose is added, H2O2 is generated by catalysis of the glucose oxidase on the beacon antibody; the generated H2O2 is catalyzed by CeO2 in the CeO2 / CdS nanocomposite to generate hydroxyl radicals, and in-situ etching of CdS in the electrode interface reduces the photocurrent, and a photocurrent intensity ratio (Iw / Ic) of a double-channel electrode has a linear relationship with the concentration of the target protein, so that quantitative analysis can be realized. The application has a sensitive response to the detection of proteins and has a fast detection speed.

The invention provides an immune detection method of an immune checkpoint detection kit, and belongs to the technical field of immune checkpoint detection kits.The immune detection method comprises the steps that an immune reaction system containing immune checkpoint antibodies is prepared, incubation is conducted under the constant temperature condition to form a sandwich type immune complex, and the sandwich type immune complex is obtained; phycoerythrin labeled streptavidin is added for fluorescence labeling, a flow cytometer is adopted for fluorescence signal detection after interference substances are removed through multiple times of cleaning, fluorescence image data are processed through an image partitioning optimization model, image processing parameters are dynamically adjusted through a signal enhancement algorithm function and a gating weight function, and the fluorescence image is obtained. A multi-scale feature extraction network based on a visual converter architecture is adopted to realize accurate processing of a complex fluorescence image, finally correlation analysis and matrix decomposition calculation are performed on fluorescence intensity data, and a detection analysis model is established to output index concentration values of immune checkpoints. The problem that complex fluorescence image data are difficult to process accurately at present is solved.

Methods and compositions for use in generating or promoting an immune response to cancer or an infection, comprising promoting differentiation of neutrophils into dendritic cells using a combination of GMCSF and (i) an immune complex comprising an antigen and an antibody comprising an Fc region that binds to FcγRIIA or FcγRIIIB, (ii) a conjugate comprising an antigen and an anti-FcγRIIIB antibody, or (iii) an anti-FcγRIIIB antibody.

The application discloses application of a CK2 inhibitor CX4945 in preparation of a medicine for preventing and / or treating lupus nephritis, and provides the CK2 inhibitor CX4945 which can significantly reduce kidney immune complex and complement C3 deposition of a lupus animal model, effectively reduce a urine protein / cratin ratio, and has no obvious side effect, and can be prepared into a lupus immunotherapy medicine, and simultaneously provides a new combined treatment mode. The medicine can be prepared into an oral medicine, is convenient for treatment, and has high patient compliance.

This invention discloses an engineered extracellular vesicle and its application in the preparation of products for treating autoimmune diseases. The engineered extracellular vesicle is either an IDO1-overexpressing engineered extracellular vesicle (MSC-IDO1-EVs) or a CSF1-overexpressing engineered extracellular vesicle (MSC-CSF1-EVs). The engineered extracellular vesicles provided by this invention exhibit significant immunosuppressive effects, reducing the secretion of inflammatory cytokines. In animal models, they effectively reduce proteinuria levels, significantly reduce blood dsDNA / ANA levels, effectively alleviate kidney damage caused by autoimmune diseases such as renal immune complex deposition, diffuse thickening of the glomerular basement membrane, and mesangial structural disorder, and reduce overall inflammation levels in mice. The therapeutic effect is significantly superior to that of unmodified MSC-EVs. The engineered extracellular vesicles provided by this invention significantly improve the therapeutic effect on autoimmune diseases.

The present invention relates to condensed piperidinyl bicyclic, metasubstituted piperidinyl, and related compounds thereof that modulate the activity of the mammalian C5a receptor by directly binding to it, for use in treating diseases, particularly monosodium urate (MSU) induced diseases, neutrophil-induced inflammatory kidney diseases, cutaneous neutrophil inflammatory diseases, and immune complex diseases.

The application discloses a platelet antibody detection and cross matching blocking chromatography kit and a detection method thereof, wherein the kit comprises a U-shaped microwell plate, a chromatography medium for separating platelet immune complexes from non-cell particle components under the action of centrifugal force, freeze-dried platelets, a platelet diluent, a platelet fluorescent staining solution comprising fluoresceinized platelet antibodies specifically labeled for platelets, biotin-labeled anti-human globulin for specifically binding with antibodies bound to the surface of the platelets, avidinized fluorescein for coupling with the biotin-labeled anti-human globulin through a biotin-avidin specific binding system, negative control serum / plasma and positive control serum / plasma. The application combines the blocking chromatography technology with a high-sensitivity flow immunofluorescence method to construct an efficient and accurate platelet antibody detection and cross matching system, which is high in specificity and sensitivity, simple in operation and stable in detection results.

The present invention relates to fused piperidinyl bicyclic compounds, meta-substituted piperidinyl compounds and related compounds that modulate the activity of the mammalian C5a receptor by direct binding to said C5a receptor for use in the treatment of disease, the diseases are in particular monosodium urate (MSU)-induced diseases, neutrophil-driven inflammatory nephropathy, skin neutrophil inflammatory diseases and immune complex diseases.

In conventional techniques, it has been difficult to increase the reduction current of gold nanoparticles, i.e., to increase sensitivity. [Solution] An object of the present invention is to provide a method for measuring a test substance, characterized by examining the presence or concentration of the test substance, the method comprising: a current measurement step of measuring a current value by controlling the potential of a working electrode to which an immune complex containing the test substance is immobilized; the immune complex comprising the test substance, a first binding substance that specifically binds to the test substance, a second binding substance that specifically binds to the test substance, and a labeling substance that binds to the second binding substance; the labeling substance is a metal microparticle comprising a core and a metal layer covering the core; and the density of the material of the core is lower than the density of the material of the metal layer.

The application discloses a carbon-coated zirconium oxide composite material, a colorimetric / photothermal dual-mode signal nano probe and application thereof in rapid quantitative detection of chikungunya virus. The colorimetric / photothermal dual-mode signal nano probe is formed by coupling a carbon-coated zirconium oxide composite nano material obtained by calcining mesoporous UiO-66 in an inert atmosphere with a chikungunya virus E2 protein monoclonal antibody. In a specific application, a chromatography test strip is constructed based on the colorimetric / photothermal dual-mode signal nano probe. The chromatography test strip comprises a nitrocellulose membrane provided with a T line and a C line. During detection, a sample and the nano probe form an immune complex and generate a colorimetric signal visible to the naked eye at the T line, and meanwhile, under the irradiation of 808 nm near-infrared laser, a temperature rise Delta T related to the concentration of a target object is generated at the T line, so that on-site rapid screening and photothermal quantitative review are realized. The chromatography test strip has both simple operation and reliable quantification, and has stronger anti-interference ability in a complex biological matrix, and is suitable for instant detection of chikungunya virus.

This application discloses the application of uridine phosphorylase 1 (UPP1) as an inhibitory target in the preparation of drugs for treating systemic lupus erythematosus (SLE), relating to the field of biomedical technology. This application is the first to discover abnormally elevated UPP1 expression in peripheral blood mononuclear cells of SLE patients, which is positively correlated with disease activity. Validation experiments demonstrate that the specific inhibitor of UPP1, BAU, can effectively inhibit UPP1 enzyme activity. In cell models, it reduces inflammatory factors and type I interferon responses induced by STING pathway activation. In SLE animal models, BAU significantly reduces splenomegaly, proteinuria, and pathological damage to the kidneys and lungs, decreases the proportion of pathogenic immune cells such as M1 macrophages, Th1 cells, and plasma cells in the spleen, and inhibits the deposition of immune complexes in the glomeruli. This invention reveals for the first time the potential of UPP1 as a novel therapeutic target for SLE and provides BAU as a candidate drug for treating SLE and related organ damage, offering a novel strategy for clinical intervention.

The application belongs to the technical field of genetic engineering antibodies, and particularly relates to an antibody for non-competitive detection of aflatoxin B1 and application thereof. The antibody comprises a nanobody of an aflatoxin B1 antigen-antibody immune complex and a monoclonal antibody against aflatoxin B1. The amino acid sequence of the nanobody of the aflatoxin B1 antigen-antibody immune complex is shown in SEQ ID NO. 1. The monoclonal antibody against aflatoxin B1 comprises a heavy chain and a light chain. The amino acid of the heavy chain is shown in SEQ ID NO. 10, and the amino acid of the light chain is shown in SEQ ID NO. 11. The antibody for non-competitive detection of aflatoxin B1 has low cost, can be prepared in a large amount through a prokaryotic expression system, is simple to prepare, has strong operability, and can be applied to non-competitive immunological analysis of aflatoxin B1.

This invention provides an antitumor agent that demonstrates efficacy against cancer cells expressing CD123, which has been reported to be overexpressed in malignant cells of a wide range of hematological malignancies. [Solution] Provided are an antibody or its antigen-binding fragment, an immune complex containing the antibody, and a method for using such CD123-binding molecules to diagnose and treat diseases such as B-cell malignancies, (a) an epitope within amino acids 101-346 of the human CD123 / IL3-Rα antigen, and (b) an antibody or its antigen-binding fragment that inhibits IL3-dependent proliferation of antigen-positive TF-1 cells.

The application provides a biomarker combination for non-invasive diagnosis of IgA nephropathy, comprising IgA-IgG immune complexes, IgG-IgA1 immune complexes, and IgA immune complexes combined with CD89. The application also provides an enzyme-linked immunoassay kit for auxiliary diagnosis of IgA nephropathy, which can jointly detect the levels of IgA-IgG immune complexes, IgG-IgA1 immune complexes, and IgA immune complexes combined with CD89. The application further provides an evaluation method for case damage of kidney tissue, which is based on the joint detection of the levels of IgA-IgG immune complexes, IgG-IgA1 immune complexes, and IgA immune complexes combined with CD89 in a sample, calculates a multi-index prediction score, and sets an evaluation threshold to determine whether short glomeruli have pathological damage. When the biomarkers are used for auxiliary diagnosis of IgA nephropathy, the biomarkers not only have the characteristics of non-invasiveness, but also have higher sensitivity, higher specificity and higher stability, and have clinical application value.

The invention provides an immune checkpoint joint detection method based on a multi-microsphere flow-type immunofluorescence method, and belongs to the technical field of multi-microsphere flow-type immunofluorescence method detection.The immune checkpoint joint detection method comprises the steps that seven fluorescent microspheres are coupled with PD-L2, TIM-3, TNFRSF7, PD-1, PD-L1, LAG-3 and CTLA-4 to capture antibodies to form a multi-detection system; the method comprises the following steps: incubating a plasma sample and an antibody microsphere mixed solution to form a first immune complex, adding a biotin-labeled detection antibody and phycoerythrin-labeled streptavidin to construct a fluorescence-labeled sandwich immune complex, detecting by using a flow cytometry to obtain fluorescence intensity data, and converting the fluorescence intensity data into a concentration value; and the optimal immune checkpoint combination is screened by applying a multi-dimensional Carnot diagram optimization algorithm, and a combination modulation factor is calculated to determine the disease risk level, so that the technical problem that the accuracy of disease risk assessment is insufficient due to the fact that multi-index collaborative analysis cannot be realized in immune checkpoint molecular detection is solved.

The invention provides a self-control integrated microfluidic system applied to exosome marker lesion detection and a use method thereof. The system comprises a first sample introduction unit (1), a second sample introduction unit (2), a third sample introduction unit (3), a first incubation unit (4), a second incubation unit (5), a first detection unit (6) and a second detection unit (7). According to the present invention, the immune complexes for detection and positive control are simultaneously generated on the chip, such that the on-chip integrated self-control detection process is achieved, the detection result error caused by the fluctuation of the detection condition is avoided, and the accuracy and the reliability of the detection are improved.